Orexo signs an exclusive development agreement for its OX17 program
Orexo has signed an exclusive development agreement with a large healthcare company, providing for joint development within Orexo’s OX17 program for gastroesophageal reflux disease (GERD), and will be discontinuing all other licensing discussions for Ox17.During this development work, Orexo will continue negotiations to enter into an appropriate global exclusive license agreement including the whole of Orexo’s Ox17 program and related intellectual property. This license agreement is anticipated during 2009. The financial terms were not disclosed.Torbjörn Bjerke, President and CEO of